Clinical trial
Randomized Controlled Trial Examining the Efficacy of Botulinum Toxin in Biopsy Scar Minimization
NCT05478551 is registered in ClinicalTrials.gov with Henry Ford Health System as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized Controlled Trial Examining the Efficacy of Botulinum Toxin in Biopsy Scar Minimization
- Lead sponsor
- Henry Ford Health System
- Phase
- Phase 2/3
- Overall status
- Active, not recruiting
- Start date
- June 1, 2022
- Completion date
- December 30, 2026
- Enrollment
- 12 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
hypertrophic scar, scar